These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

300 related items for PubMed ID: 15623607

  • 1. Human autologous tumor-specific T-cell responses induced by liposomal delivery of a lymphoma antigen.
    Neelapu SS, Baskar S, Gause BL, Kobrin CB, Watson TM, Frye AR, Pennington R, Harvey L, Jaffe ES, Robb RJ, Popescu MC, Kwak LW.
    Clin Cancer Res; 2004 Dec 15; 10(24):8309-17. PubMed ID: 15623607
    [Abstract] [Full Text] [Related]

  • 2. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
    Ruffini PA, Neelapu SS, Kwak LW, Biragyn A.
    Haematologica; 2002 Sep 15; 87(9):989-1001. PubMed ID: 12217812
    [Abstract] [Full Text] [Related]

  • 3. Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma.
    Timmerman JM, Singh G, Hermanson G, Hobart P, Czerwinski DK, Taidi B, Rajapaksa R, Caspar CB, Van Beckhoven A, Levy R.
    Cancer Res; 2002 Oct 15; 62(20):5845-52. PubMed ID: 12384547
    [Abstract] [Full Text] [Related]

  • 4. Therapeutic lymphoma vaccines: importance of T-cell immunity.
    Neelapu SS, Lee ST, Qin H, Cha SC, Woo AF, Kwak LW.
    Expert Rev Vaccines; 2006 Jun 15; 5(3):381-94. PubMed ID: 16827622
    [Abstract] [Full Text] [Related]

  • 5. Phase I trial of a novel intradermal idiotype vaccine in patients with advanced B-cell lymphoma: specific immune responses despite profound immunosuppression.
    Bertinetti C, Zirlik K, Heining-Mikesch K, Ihorst G, Dierbach H, Waller CF, Veelken H.
    Cancer Res; 2006 Apr 15; 66(8):4496-502. PubMed ID: 16618777
    [Abstract] [Full Text] [Related]

  • 6. Anti-idiotypic Immunotherapy in follicular lymphoma patients: results of a long follow-up study.
    Yáñez R, Barrios Y, Ruiz E, Cabrera R, Díaz-Espada F.
    J Immunother; 2008 Apr 15; 31(3):310-2. PubMed ID: 18317357
    [Abstract] [Full Text] [Related]

  • 7. Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma.
    Inogès S, Rodrìguez-Calvillo M, Zabalegui N, Lòpez-Dìaz de Cerio A, Villanueva H, Soria E, Suárez L, Rodríguez-Caballero A, Pastor F, García-Muñóz R, Panizo C, Pèrez-Calvo J, Melero I, Rocha E, Orfao A, Bendandi M, Grupo Español de Linfomas/Trasplante Autologo de Medula Oseo study group, Programa para el Estudio y Tratamiento de Hemopatias Malignas study group.
    J Natl Cancer Inst; 2006 Sep 20; 98(18):1292-301. PubMed ID: 16985248
    [Abstract] [Full Text] [Related]

  • 8. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma.
    Bendandi M, Gocke CD, Kobrin CB, Benko FA, Sternas LA, Pennington R, Watson TM, Reynolds CW, Gause BL, Duffey PL, Jaffe ES, Creekmore SP, Longo DL, Kwak LW.
    Nat Med; 1999 Oct 20; 5(10):1171-7. PubMed ID: 10502821
    [Abstract] [Full Text] [Related]

  • 9. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors.
    Kwak LW, Campbell MJ, Czerwinski DK, Hart S, Miller RA, Levy R.
    N Engl J Med; 1992 Oct 22; 327(17):1209-15. PubMed ID: 1406793
    [Abstract] [Full Text] [Related]

  • 10. Translational development of vaccination strategies in follicular NHL.
    Sakamaki I, Qin H, Kwak LW.
    Best Pract Res Clin Haematol; 2011 Jun 22; 24(2):295-304. PubMed ID: 21658625
    [Abstract] [Full Text] [Related]

  • 11. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine.
    Welters MJ, Kenter GG, Piersma SJ, Vloon AP, Löwik MJ, Berends-van der Meer DM, Drijfhout JW, Valentijn AR, Wafelman AR, Oostendorp J, Fleuren GJ, Offringa R, Melief CJ, van der Burg SH.
    Clin Cancer Res; 2008 Jan 01; 14(1):178-87. PubMed ID: 18172269
    [Abstract] [Full Text] [Related]

  • 12. Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype.
    Weng WK, Czerwinski D, Timmerman J, Hsu FJ, Levy R.
    J Clin Oncol; 2004 Dec 01; 22(23):4717-24. PubMed ID: 15483014
    [Abstract] [Full Text] [Related]

  • 13. Inhibition of a vaccine-induced anti-tumor B cell response by soluble protein antigen in the absence of continuing T cell help.
    Savelyeva N, King CA, Vitetta ES, Stevenson FK.
    Proc Natl Acad Sci U S A; 2005 Aug 02; 102(31):10987-92. PubMed ID: 16037207
    [Abstract] [Full Text] [Related]

  • 14. HER2-specific T-cell immune responses in patients vaccinated with truncated HER2 protein complexed with nanogels of cholesteryl pullulan.
    Kitano S, Kageyama S, Nagata Y, Miyahara Y, Hiasa A, Naota H, Okumura S, Imai H, Shiraishi T, Masuya M, Nishikawa M, Sunamoto J, Akiyoshi K, Kanematsu T, Scott AM, Murphy R, Hoffman EW, Old LJ, Shiku H.
    Clin Cancer Res; 2006 Dec 15; 12(24):7397-405. PubMed ID: 17189412
    [Abstract] [Full Text] [Related]

  • 15. HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities.
    Santin AD, Bellone S, Palmieri M, Ravaggi A, Romani C, Tassi R, Roman JJ, Burnett A, Pecorelli S, Cannon MJ.
    Gynecol Oncol; 2006 Mar 15; 100(3):469-78. PubMed ID: 16249018
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Induction of p53-specific immune responses in colorectal cancer patients receiving a recombinant ALVAC-p53 candidate vaccine.
    van der Burg SH, Menon AG, Redeker A, Bonnet MC, Drijfhout JW, Tollenaar RA, van de Velde CJ, Moingeon P, Kuppen PJ, Offringa R, Melief CJ.
    Clin Cancer Res; 2002 May 15; 8(5):1019-27. PubMed ID: 12006514
    [Abstract] [Full Text] [Related]

  • 18. Tumor antigen immunization of sibling stem cell transplant donors in multiple myeloma.
    Neelapu SS, Munshi NC, Jagannath S, Watson TM, Pennington R, Reynolds C, Barlogie B, Kwak LW.
    Bone Marrow Transplant; 2005 Aug 15; 36(4):315-23. PubMed ID: 15968284
    [Abstract] [Full Text] [Related]

  • 19. Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma.
    Neelapu SS, Kwak LW, Kobrin CB, Reynolds CW, Janik JE, Dunleavy K, White T, Harvey L, Pennington R, Stetler-Stevenson M, Jaffe ES, Steinberg SM, Gress R, Hakim F, Wilson WH.
    Nat Med; 2005 Sep 15; 11(9):986-91. PubMed ID: 16116429
    [Abstract] [Full Text] [Related]

  • 20. Interleukin-6 fused to an anti-idiotype antibody in a vaccine increases the specific humoral immune response against CA125+ (MUC-16) ovarian cancer.
    Reinartz S, Hombach A, Köhler S, Schlebusch H, Wallwiener D, Abken H, Wagner U.
    Cancer Res; 2003 Jun 15; 63(12):3234-40. PubMed ID: 12810653
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.